<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Inherited and acquired <z:hpo ids='HP_0100724'>thrombophilia</z:hpo> are associated with recurrent pregnancy loss (RPL) </plain></SENT>
<SENT sid="1" pm="."><plain>We have evaluated the efficacy and safety of the low molecular weight <z:chebi fb="5" ids="28304">heparin</z:chebi> enoxaparin in 50 women, (mean age 26 +/- 3 years) with RPL (&gt; or =3 losses in 1st, &gt; or =2 losses in 2nd and &gt; or =1 loss in 3rd trimester) who were found to harbor <z:hpo ids='HP_0100724'>thrombophilia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Twenty-seven had a solitary thrombophilic defect, and twenty-three women had combined thrombophilic defects: 17--two defects and 6--three defects </plain></SENT>
<SENT sid="3" pm="."><plain>Following diagnosis of <z:hpo ids='HP_0100724'>thrombophilia</z:hpo>, sixty-one subsequent pregnancies were treated with the low molecular weight <z:chebi fb="5" ids="28304">heparin</z:chebi> enoxaparin throughout gestation until 4 weeks after delivery </plain></SENT>
<SENT sid="4" pm="."><plain>Dosage was 40 mg/day in women with solitary defect and 80 mg/day in combined defects </plain></SENT>
<SENT sid="5" pm="."><plain>Aspirin, 75 mg daily was given in addition to enoxaparin to women with <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Forty-six out of 61 (75%) gestations treated by enoxaparin resulted in live birth compared to only 38/193 (20%) of the untreated pregnancies in these 50 women prior to diagnosis of <z:hpo ids='HP_0100724'>thrombophilia</z:hpo> (p &lt;0.00001) </plain></SENT>
<SENT sid="7" pm="."><plain>In 23 women without a single living child following 82 untreated gestations, antithrombotic therapy resulted in 26/31 (84%) successful deliveries (p &lt;0.0001) </plain></SENT>
<SENT sid="8" pm="."><plain>In 20 women with a prior living child, antithrombotic therapy improved successful delivery from 33/86 (38%) to 20/21 (95%) (p &lt;0.0001) </plain></SENT>
<SENT sid="9" pm="."><plain>Enoxaparin dose of 40 mg/day resulted in live birth in 24/35 (69%) of gestations, compared to 19/23 (83%) gestations in women treated with 80 mg/day (p = 0.37) </plain></SENT>
<SENT sid="10" pm="."><plain>Only one thrombotic episode and one mild-<z:mp ids='MP_0001914'>bleeding</z:mp> episode were noticed during enoxaparin therapy </plain></SENT>
<SENT sid="11" pm="."><plain>Enoxaparin is safe and effective in prevention of pregnancy loss in women with inherited and acquired <z:hpo ids='HP_0100724'>thrombophilia</z:hpo> </plain></SENT>
</text></document>